STOCK TITAN

Theriva Biologics, Inc. - $TOVX STOCK NEWS

Welcome to our dedicated page for Theriva Biologics news (Ticker: $TOVX), a resource for investors and traders seeking the latest updates and insights on Theriva Biologics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Theriva Biologics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Theriva Biologics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.46%
Tags
-
Rhea-AI Summary
Theriva Biologics appoints Dr. Ramon Alemany as Senior Vice President of Discovery to strengthen collaboration with ICO and IDIBELL
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
Rhea-AI Summary
Theriva Biologics plans to host a conference call on May 11, 2023, to discuss its financial results for Q1 2023 and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.06%
Tags
conferences earnings
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.48%
Tags
conferences
Theriva Biologics, Inc.

NYSE:TOVX

TOVX Rankings

TOVX Stock Data

6.40M
16.82M
1.93%
6.14%
2.4%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
ROCKVILLE

About TOVX

synthetic biologics, inc. (nyse mkt: syn) is a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients. the company's lead candidates poised for phase 3 development are: (1) syn-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (ibs-c), and (2) syn-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (iv) beta-lactam antibiotics for the prevention of c. difficile infection (cdi), antibiotic-associated diarrhea (aad) and the emergence of antimicrobial-resistance (amr). the company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (pku).